Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 29.15 as of 2026-10-06T16:38:45.007Z.
Consensus retrieved: 2026-10-06T15:20:56.164Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:38:45.007Z.
Quote observation: 2026-10-06T16:35:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3dea8458169e79ebd39e38f4dddaf580eb07bc5d686b80f38d040b1adcece34b
Forward PE Ratio (29.15) = Dated Quote Price ($40.68) / Consensus Forward EPS ($1.40)
FORWARD PE RATIO
29.15
SECTOR MEDIAN · HEALTHCARE
19.63
median of 178 covered companies
CURRENT VS SECTOR MEDIAN
+48.54%
vs the sector median at left
The Pennant Group, Inc.
Market Cap
$1.41B
Forward PE Ratio
29.15
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| The Pennant Group, Inc. (PNTG) | $1.41B | 29.15 |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.41B | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | N/A |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | N/A |
| Certara, Inc. (CERT)vs › | $1.46B | 27.52 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 17.76 |
| Omeros Corporation (OMER)vs › | $1.35B | 20.65 |
Trailing P/E
45.2
reported TTM EPS
Forward P/E
29.1
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $1.40 implies +55.6% EPS growth vs the reported trailing $0.90.
At the dated quote price of $40.68, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $1.40 | $1.39 – $1.41 | 3 | 29.1x |
| 2027-12-31 | $1.58 | $1.57 – $1.60 | 3 | 25.7x |
| 2028-12-31 | $1.84 | $1.82 – $1.87 | 2 | 22.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
